Heng Zhang

Heng Zhang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Cancer Letters
Verified
Journal Article
Closed access
QWQiang Wang
Qiang Wang
XJXiaoli Ju
Xiaoli Ju
JWJiayou Wang
Jiayou Wang
YFYu Fan
Yu Fan
MRMeijia Ren
Meijia Ren
HZHeng Zhang
Heng Zhang

1 June 2021 in Biochimie
Verified
Journal Article
Closed access
XJXiaoli Ju
Xiaoli Ju
ZYZhilong Yang
Zhilong Yang
HZHeng Zhang
Heng Zhang
QWQiang Wang
Qiang Wang

26 November 2021 in Toxicology Research
Verified
Journal Article
Closed access
QWQiang Wang
Qiang Wang
JWJing Wang
Jing Wang
JWJiayou Wang
Jiayou Wang
XJXiaoli Ju
Xiaoli Ju
HZHeng Zhang
Heng Zhang
Shikonin is one of the major bioactive components of Lithospermum erythrorhizon. It has a good killing effect in a variety of tumor cells. Its antitumor effect involves multiple targets and pathways and has received extensive attention and study in recent years. In this review, we systematically review recent progress in determining the antitumor mechanism of shikonin and its derivatives, specifically their induction of reactive oxygen species production, inhibition of EGFR and PI3K/AKT signaling pathway activation, inhibition of angiogenesis and induction of apoptosis and necroptosis. We also discuss the application of nanoparticles loaded with shikonin in the targeted therapy of various cancers. Finally, we suggest new strategies for the clinical application of shikonin and its derivatives.

19 October 2018 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
QWQiang Wang
Qiang Wang
FFFan Feng
Fan Feng
JWJiayou Wang
Jiayou Wang
MRMeijia Ren
Meijia Ren
ZSZhonggang Shi
Zhonggang Shi
XJXiaoli Ju
Xiaoli Ju
Liver X receptors (LXRs) are involved in various diseases associated with lipid disorders, and in regulating cancer cell proliferation. However, the underlying molecular mechanisms, especially those in gastric cancer (GC) remain to be clarified. In this study, immunohistochemistry analysis revealed that LXRβ was mainly expressed in GC tissue, with less expression in adjacent normal tissues. The LXRβ agonist T0901317 efficiently suppressed the proliferation and colony formation of various GC cell lines. We further showed that LXRβ translocated from the cytoplasm to the nucleus when activated by T0901317. LXRβ nuclear localization suppressed the activation of Wnt signalling and decreased the expression of target genes such as MYC, BMP4, and MMP7 through binding to their promoters. Moreover, we demonstrated that the LXR agonist efficiently suppressed GC tumour growth in a nude mouse xenograft model. Taken together, these results revealed that LXRβ agonist inhibited GC cells proliferation by suppressing Wnt signalling via LXRβ relocalization. The results strongly suggest that LXRβ could be a promising target in GC therapy.

1 May 2021 in Life Sciences
Verified
Journal Article
Closed access
QWQiang Wang
Qiang Wang
JWJing Wang
Jing Wang
JWJiayou Wang
Jiayou Wang
HZHeng Zhang
Heng Zhang

29 July 2025 in Food Chemistry
Verified
Journal Article
Closed access
QWQiang Wang
Qiang Wang
FWFeifei Wang
Feifei Wang
ZHZengqing Huang
Zengqing Huang
JZJiacheng Zheng
Jiacheng Zheng
XLXinyao Liang
Xinyao Liang
HZHeng Zhang
Heng Zhang